Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Inhibition of CD26 Peptidase Using Sitagliptin to Enhance Engraftment After Umbilical Cord Blood Transplantation for Adults With Hematological Malignancies

NCT00862719 is registered in ClinicalTrials.gov with Indiana University as lead sponsor.

NCT NCT00862719
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00862719 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Inhibition of CD26 Peptidase Using Sitagliptin to Enhance Engraftment After Umbilical Cord Blood Transplantation for Adults With Hematological Malignancies
Lead sponsor
Indiana University
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2009
Completion date
February 28, 2015
Enrollment
29 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, leukemia, myelogenous, chronic, leukemia, myeloid, acute, lymphoma, non-hodgkin, myelodysplasia